How to research a manufacturer across FDA names
Check applicant and recalling-firm names without confusing spelling variations, subsidiaries, and unrelated companies.
Read the guide →Medical-device intelligence
Research HORIBA ABX SAS in public FDA records: applicant and recalling-firm names, product codes, clearance history, and recall records.
This profile groups matching applicant and recalling-firm names found in covered FDA records. It does not imply a complete corporate family, current ownership, or every product marketed under a brand.
18 clearance records and 0 recall records in the covered releases, across 1 source company names and 11 product codes. Dated history runs from Oct 16, 2009 to Sep 14, 2026.
| Month | 510(k) decisions | Recall initiations |
|---|---|---|
| October 2025 | 0 | 0 |
| November 2025 | 0 | 0 |
| December 2025 | 0 | 0 |
| January 2026 | 0 | 0 |
| February 2026 | 0 | 0 |
| March 2026 | 0 | 0 |
| April 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| June 2026 | 0 | 0 |
| July 2026 | 0 | 0 |
| August 2026 | 0 | 0 |
| September 2026 | 1 | 0 |
| October 2026 | 0 | 0 |
| Device / record | Company in FDA record | Source | Source date |
|---|---|---|---|
| Yumizen H550K260781 · GKZ | HORIBA ABX SAS | 510(k) | Sep 14, 2026FDA decision date |
| Yumizen H2500K232946 · GKZ | HORIBA ABX SAS | 510(k) | May 21, 2024FDA decision date |
| Yumizen C1200 Creatinine PAPK193649 · JFY | HORIBA ABX SAS | 510(k) | May 10, 2021FDA decision date |
| Yumizen C1200 Immunoglobulin A, Yumizen C1200 Immunoglobulin G, Yumizen C1200 Immunoglobulin MK193525 · CZP | HORIBA ABX SAS | 510(k) | Jun 26, 2020FDA decision date |
| Yumizen C1200 CRPK192028 · DCK | HORIBA ABX SAS | 510(k) | Jun 25, 2020FDA decision date |
| Yumizen C1200 Ferritin, Yumizen C1200 Transferrin, Yumizen C1200 Rheumatoid FactorK191562 · DBF | HORIBA ABX SAS | 510(k) | Mar 6, 2020FDA decision date |
| Yumizen C1200 CRPK191993 · DCK | HORIBA ABX SAS | 510(k) | Oct 3, 2019FDA decision date |
| Yumizen C1200 ALP, Yumizen C1200 AlbuminK191245 · CJE | HORIBA ABX SAS | 510(k) | Aug 30, 2019FDA decision date |
| Yumizen C1200 Calcium AS, Yumizen C1200 Creatinine JaffeK191396 · CJY | HORIBA ABX SAS | 510(k) | Jul 26, 2019FDA decision date |
| ABX MICROS ES 60 OT and ABX MICROS ES 60 CTK170353 · GKZ | HORIBA ABX SAS | 510(k) | Nov 1, 2017FDA decision date |
| PENTRA XLRK151133 · GKZ | HORIBA ABX SAS | 510(k) | Dec 9, 2015FDA decision date |
| ABX MICROS ES 60 CT; (OPEN TUBE MODEL), (CLOSE TUBE MODEL)K141161 · GKZ | HORIBA ABX SAS | 510(k) | Dec 20, 2014FDA decision date |
| ABX PENTRA MICRO ALB CONTROL L/HK133676 · JJY | HORIBA ABX SAS | 510(k) | Jul 11, 2014FDA decision date |
| ABX PENTRA CALCIUM AS CP, ABX PENTRA URINE CONTROL L/H, ABX PENTRA MULTICAL, ABX PENTRA N CONTROL, AND ABX PENTRA P CONTK123171 · CJY | HORIBA ABX SAS | 510(k) | Jul 3, 2013FDA decision date |
| ABX PENTRA CREATININE 120 CP; ABX PENTRA MULTICAL; ABX PENTRA N CONTROL; ABX PENTRA P CONTROL; ABX PENTRA URINE CONTROLK110530 · CGX | HORIBA ABX SAS | 510(k) | Apr 30, 2012FDA decision date |
| PENTRA C200, ISE MODULE AND ABX PENTRA GLUCOSE HK CP REAGENTK103788 · CFR | HORIBA ABX SAS | 510(k) | Nov 8, 2011FDA decision date |
| ABX PENTRA ENZYMATIC CREATININE CP, ABX PENTRA MULTICAL, ABX PENTRA N CONTROL, ABX PENTRA P CONTROL, AND ABX PENTRA URINK110137 · JFY | HORIBA ABX SAS | 510(k) | Aug 10, 2011FDA decision date |
| ABX PENTRA TPU CAL, MODEL A11A01898K092570 · JIT | HORIBA ABX SAS | 510(k) | Oct 16, 2009FDA decision date |
Check applicant and recalling-firm names without confusing spelling variations, subsidiaries, and unrelated companies.
Read the guide →Build a repeatable clearance search using FDA applicant names, product codes, decision dates, and original records.
Read the guide →FDA dataset:
Last successful check: Nov 22, 2026
Source classifications may change.
FDA dataset:
Last successful check: Nov 22, 2026
FDA publishes this dataset monthly.
FDA dataset:
Last successful check: Nov 22, 2026
FDA publishes this dataset weekly.
Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.